{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:48:36Z","timestamp":1775162916292,"version":"3.50.1"},"reference-count":141,"publisher":"Bentham Science Publishers Ltd.","issue":"7","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Diabetes mellitus is a major metabolic disorder that has now emerged as an epidemic,\nand it affects the brain through an array of pathways. Patients with diabetes mellitus can develop\npathological changes in the brain, which eventually take the shape of mild cognitive impairment,\nwhich later progresses to Alzheimer\u2019s disease. A number of preclinical and clinical studies have demonstrated\nthis fact, and molecular pathways, such as amyloidogenesis, oxidative stress, inflammation,\nand impaired insulin signaling, are found to be identical in diabetes mellitus and dementia.\nHowever, the critical player involved in the vicious cycle of diabetes mellitus and dementia is insulin,\nwhose signaling, when impaired in diabetes mellitus (both type 1 and 2), leads to a decline in\ncognition, although other pathways are also essential contributors. Moreover, it is not only the case\nthat patients with diabetes mellitus indicate cognitive decline at a later stage, but many patients\nwith Alzheimer\u2019s disease also reflect symptoms of diabetes mellitus, thus creating a vicious cycle\ninculcating a web of complex molecular mechanisms and hence categorizing Alzheimer\u2019s disease\nas \u2018brain diabetes.\u2019 Thus, it is practical to suggest that anti-diabetic drugs are beneficial in\nAlzheimer\u2019s disease. However, only smaller trials have showcased positive outcomes mainly because\nof the late onset of therapy. Therefore, it is extremely important to develop more of such\nmolecules that target insulin in patients with dementia along with such methods that diagnose impaired\ninsulin signaling and the associated cognitive decline so that early therapy may be initiated\nand the progression of the disease can be prevented.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527320666211110115257","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T04:29:20Z","timestamp":1636604960000},"page":"542-556","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Molecular and Biochemical Pathways Encompassing Diabetes Mellitus\nand Dementia"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0993-7708","authenticated-orcid":true,"given":"Tapan","family":"Behl","sequence":"first","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpita","family":"Arora","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aayush","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhbir","family":"Singh","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Sharma","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Amity Institute of Pharmacy, Amity University, Haryana, India | Natural & Medical Sciences Research Centre, University of Nizwa, Nizwa, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Al-Harrasi","sequence":"additional","affiliation":[{"name":"Natural & Medical Sciences Research Centre, University of Nizwa, Nizwa, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Bungau","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebrahim","family":"Mostafavi","sequence":"additional","affiliation":[{"name":"Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA | Department of Medicine, Stanford University\nSchool of Medicine, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","volume":"53","author":"Ott A.","year":"1999","unstructured":"Ott A.; Stolk R.P.; van Harskamp F.; Pols H.A.; Hofman A.; Breteler M.M.; Diabetes mellitus and the risk of dementia: the rotterdam study. Neurology 1999,53(9),1937-1942","journal-title":"Neurology"},{"key":"ref=2","first-page":"373","volume":"14","author":"Kroner Z.","year":"2009","unstructured":"Kroner Z.; The relationship between Alzheimer\u2019s disease and diabetes: type 3 diabetes? Altern Med Rev 2009,14(4),373-379","journal-title":"Altern Med Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00023210-200822010-00001","volume":"22","author":"Jiang Q.","year":"2008","unstructured":"Jiang Q.; Heneka M.; Landreth G.E.; The role of peroxisome proliferator-activated receptor-\u03b3 PPAR\u03b3) in Alzheimer\u2019s disease. CNS Drugs 2008,22(1),1-4","journal-title":"CNS Drugs"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","volume":"383","author":"Kahn S.E.","year":"2014","unstructured":"Kahn S.E.; Cooper M.E.; Del Prato S.; Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014,383(9922),1068-1083","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"Prince M.","year":"2013","unstructured":"Prince M.; Bryce R.; Albanese E.; Wimo A.; Ribeiro W.; Ferri C.P.; The global prevalence of dementia: a systematic review and meta-analysis. Alzheimers Dement 2013,9(1),63-75.e2","journal-title":"Alzheimers Dement"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1474-4422(05)70284-2","volume":"5","author":"Biessels G.J.","year":"2006","unstructured":"Biessels G.J.; Staekenborg S.; Brunner E.; Brayne C.; Scheltens P.; Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006,5(1),64-74","journal-title":"Lancet Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-1-4419-8969-7_8","author":"Hoyer S.","year":"2004","unstructured":"Hoyer S.; Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Frontiers in Clinical Neuroscience Advances in Experimental Medicine and Biology 2004,135-152","journal-title":"Frontiers in Clinical Neuroscience Advances in Experimental Medicine and Biology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-2005-7107","volume":"7","author":"Steen E.","year":"2005","unstructured":"Steen E.; Terry B.M.J.; Rivera E.J.; Cannon J.L.; Neely T.R.; Tavares R.; Xu X.J.; Wands J.R.; de la Monte S.M.; Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer-s disease-is this type 3 diabetes? J Alzheimers Dis 2005,7(1),63-80","journal-title":"J Alzheimers Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JAD-2005-7106","volume":"7","author":"de la Monte S.M.","year":"2005","unstructured":"de la Monte S.M.; Wands J.R.; Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer\u2019s disease. J Alzheimers Dis 2005,7(1),45-61","journal-title":"J Alzheimers Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s007020200028","volume":"109","author":"Hoyer S.","year":"2002","unstructured":"Hoyer S.; The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm (Vienna) 2002,109(3),341-360","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JAD-2005-8304","volume":"8","author":"Rivera E.J.","year":"2005","unstructured":"Rivera E.J.; Goldin A.; Fulmer N.; Tavares R.; Wands J.R.; de la Monte S.M.; Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer\u2019s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005,8(3),247-268","journal-title":"J Alzheimers Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/archneur.62.7.1043-a","volume":"62","author":"Craft S.","year":"2005","unstructured":"Craft S.; Insulin resistance and cognitive impairment: a view through the prism of epidemiology. Arch Neurol 2005,62(7),1043-1044","journal-title":"Arch Neurol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"7084","DOI":"10.1523\/JNEUROSCI.23-18-07084.2003","volume":"23","author":"Schubert M.","year":"2003","unstructured":"Schubert M.; Brazil D.P.; Burks D.J.; Kushner J.A.; Ye J.; Flint C.L.; Farhang-Fallah J.; Dikkes P.; Warot X.M.; Rio C.; Corfas G.; White M.F.; Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003,23(18),7084-7092","journal-title":"J Neurosci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1073\/pnas.0308724101","volume":"101","author":"Schubert M.","year":"2004","unstructured":"Schubert M.; Gautam D.; Surjo D.; Ueki K.; Baudler S.; Schubert D.; Kondo T.; Alber J.; Galldiks N.; K\u00fcstermann E.; Arndt S.; Jacobs A.H.; Krone W.; Kahn C.R.; Br\u00fcning J.C.; Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 2004,101(9),3100-3105","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1530-0277.2000.tb02044.x","volume":"24","author":"de la Monte S.M.","year":"2000","unstructured":"de la Monte S.M.; Ganju N.; Banerjee K.; Brown N.V.; Luong T.; Wands J.R.; Partial rescue of ethanol-induced neuronal apoptosis by growth factor activation of phosphoinositol-3-kinase. Alcohol Clin Exp Res 2000,24(5),716-726","journal-title":"Alcohol Clin Exp Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/PL00000829","volume":"58","author":"de la Monte S.M.","year":"2001","unstructured":"de la Monte S.M.; Neely T.R.; Cannon J.; Wands J.R.; Ethanol impairs insulin-stimulated mitochondrial function in cerebellar granule neurons. Cell Mol Life Sci 2001,58(12-13),1950-1960","journal-title":"Cell Mol Life Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s00018-002-8475-x","volume":"59","author":"de la Monte S.M.","year":"2002","unstructured":"de la Monte S.M.; Wands J.R.; Chronic gestational exposure to ethanol impairs insulin-stimulated survival and mitochondrial function in cerebellar neurons. Cell Mol Life Sci 2002,59(5),882-893","journal-title":"Cell Mol Life Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"26929","DOI":"10.1074\/jbc.M300401200","volume":"278","author":"Xu J.","year":"2003","unstructured":"Xu J.; Yeon J.E.; Chang H.; Tison G.; Chen G.J.; Wands J.; de la Monte S.; Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. J Biol Chem 2003,278(29),26929-26937","journal-title":"J Biol Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/193229680800200619","volume":"2","author":"de la Monte S.M.","year":"2008","unstructured":"de la Monte S.M.; Wands J.R.; Alzheimer\u2019s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008,2(6),1101-1113","journal-title":"J Diabetes Sci Technol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(14)70249-2","volume":"14","author":"Koekkoek P.S.","year":"2015","unstructured":"Koekkoek P.S.; Kappelle L.J.; van den Berg E.; Rutten G.E.; Biessels G.J.; Cognitive function in patients with diabetes mellitus: guidance for daily care. Lancet Neurol 2015,14(3),329-340","journal-title":"Lancet Neurol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.0954-6820.1980.tb01217.x","volume":"208","author":"Adolfsson R.","year":"1980","unstructured":"Adolfsson R.; Bucht G.; Lithner F.; Winblad B.; Hypoglycemia in Alzheimer\u2019s disease. Acta Med Scand 1980,208(5),387-388","journal-title":"Acta Med Scand"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/ageing\/23.5.396","volume":"23","author":"Razay G.","year":"1994","unstructured":"Razay G.; Wilcock G.K.; Hyperinsulinaemia and Alzheimer\u2019s disease. Age Ageing 1994,23(5),396-399","journal-title":"Age Ageing"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0166-4328(95)00153-0","volume":"75","author":"Messier C.","year":"1996","unstructured":"Messier C.; Gagnon M.; Glucose regulation and cognitive functions: relation to Alzheimer\u2019s disease and diabetes. Behav Brain Res 1996,75(1-2),1-11","journal-title":"Behav Brain Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.brainresrev.2007.09.001","volume":"56","author":"Li L.","year":"2007","unstructured":"Li L.; H\u00f6lscher C.; Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Brain Res Rev 2007,56(2),384-402","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00018-009-9070-1","volume":"66","author":"G\u00f6tz J.","year":"2009","unstructured":"G\u00f6tz J.; Ittner L.M.; Lim Y.A.; Common features between diabetes mellitus and Alzheimer\u2019s disease. Cell Mol Life Sci 2009,66(8),1321-1325","journal-title":"Cell Mol Life Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4239\/wjd.v1.i3.68","volume":"1","author":"Saini V.","year":"2010","unstructured":"Saini V.; Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes 2010,1(3),68-75","journal-title":"World J Diabetes"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3988\/jcn.2011.7.1.10","volume":"7","author":"Park S.A.","year":"2011","unstructured":"Park S.A.; A common pathogenic mechanism linking type-2 diabetes and Alzheimer\u2019s disease: evidence from animal models. J Clin Neurol 2011,7(1),10-18","journal-title":"J Clin Neurol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S1262-3636(07)70298-7","volume":"32","author":"Pasquier F.","year":"2006","unstructured":"Pasquier F.; Boulogne A.; Leys D.; Fontaine P.; Diabetes mellitus and dementia. Diabetes Metab 2006,32(5 Pt 1),403-414","journal-title":"Diabetes Metab"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/jnnp.2006.110361","volume":"78","author":"Verdelho A.","year":"2007","unstructured":"Verdelho A.; Madureira S.; Ferro J.M.; Basile A.M.; Chabriat H.; Erkinjuntti T.; Fazekas F.; Hennerici M.; O\u2019Brien J.; Pantoni L.; Salvadori E.; Scheltens P.; Visser M.C.; Wahlund L.O.; Waldemar G.; Wallin A.; Inzitari D.; Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry 2007,78(12),1325-1330","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15216549800201002","volume":"44","author":"Biju M.P.","year":"1998","unstructured":"Biju M.P.; Paulose C.S.; Brain glutamate dehydrogenase changes in streptozotocin diabetic rats as a function of age. Biochem Mol Biol Int 1998,44(1),1-7","journal-title":"Biochem Mol Biol Int"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neurobiolaging.2005.09.003","volume":"26","author":"Winocur G.","year":"2005","unstructured":"Winocur G.; Greenwood C.E.; Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol Aging 2005,26(1)(Suppl. 1),46-49","journal-title":"Neurobiol Aging"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/01.wad.0000213866.86934.7e","volume":"20","author":"Craft S.","year":"2006","unstructured":"Craft S.; Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 2006,20(4),298-301","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JAD-2006-10113","volume":"10","author":"de la Monte S.M.","year":"2006","unstructured":"de la Monte S.M.; Tong M.; Lester-Coll N.; Plater M.; Wands J.R.; Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer\u2019s disease. J Alzheimers Dis 2006,10(1),89-109","journal-title":"J Alzheimers Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/ncpneuro0124","volume":"2","author":"Haan M.N.","year":"2006","unstructured":"Haan M.N.; Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer\u2019s disease. Nat Clin Pract Neurol 2006,2(3),159-166","journal-title":"Nat Clin Pract Neurol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neurobiolaging.2004.11.011","volume":"27","author":"Watson G.S.","year":"2006","unstructured":"Watson G.S.; Bernhardt T.; Reger M.A.; Cholerton B.A.; Baker L.D.; Peskind E.R.; Asthana S.; Plymate S.R.; Fr\u00f6lich L.; Craft S.; Insulin effects on CSF norepinephrine and cognition in Alzheimer\u2019s disease. Neurobiol Aging 2006,27(1),38-41","journal-title":"Neurobiol Aging"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fnins.2020.00229","volume":"14","author":"Garcia-Serrano A.M.","year":"2020","unstructured":"Garcia-Serrano A.M.; Duarte J.M.N.; Brain metabolism alterations in type 2 diabetes: what did we learn from diet-induced diabetes models? Front Neurosci 2020,14,229","journal-title":"Front Neurosci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4239\/wjd.v6.i12.1223","volume":"6","author":"Sandhir R.","year":"2015","unstructured":"Sandhir R.; Gupta S.; Molecular and biochemical trajectories from diabetes to Alzheimer\u2019s disease: a critical appraisal. World J Diabetes 2015,6(12),1223-1242","journal-title":"World J Diabetes"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bbadis.2008.10.014","volume":"1792","author":"Zhao W.Q.","year":"2009","unstructured":"Zhao W.Q.; Townsend M.; Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer\u2019s disease. Biochim Biophys Acta 2009,1792(5),482-496","journal-title":"Biochim Biophys Acta"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00549079","volume":"359","author":"Westermark P.","year":"1973","unstructured":"Westermark P.; Fine structure of islets of Langerhans in insular amyloidosis. Virchows Arch A Pathol Pathol Anat 1973,359(1),1-18","journal-title":"Virchows Arch A Pathol Pathol Anat"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1073\/pnas.84.11.3881","volume":"84","author":"Westermark P.","year":"1987","unstructured":"Westermark P.; Wernstedt C.; Wilander E.; Hayden D.W.; O\u2019Brien T.D.; Johnson K.H.; Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide- like protein also present in normal islet cells. Proc Natl Acad Sci USA 1987,84(11),3881-3885","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","volume":"84","author":"Cooper G.J.","year":"1987","unstructured":"Cooper G.J.; Willis A.C.; Clark A.; Turner R.C.; Sim R.B.; Reid K.B.; Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987,84(23),8628-8632","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1098\/rstb.2006.1858","volume":"361","author":"Woods S.C.","year":"2006","unstructured":"Woods S.C.; Lutz T.A.; Geary N.; Langhans W.; Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci 2006,361(1471),1219-1235","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.npep.2006.07.001","volume":"40","author":"Arora S.","year":"2006","unstructured":"Arora S.; Role of neuropeptides in appetite regulation and obesity-a review. Neuropeptides 2006,40(6),375-401","journal-title":"Neuropeptides"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0014-5793(89)81467-X","volume":"251","author":"Betsholtz C.","year":"1989","unstructured":"Betsholtz C.; Christmansson L.; Engstr\u00f6m U.; Rorsman F.; Svensson V.; Johnson K.H.; Westermark P.; Sequence divergence in a specific region of Islet Amyloid Polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett 1989,251(1-2),261-264","journal-title":"FEBS Lett"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","volume":"87","author":"Westermark P.","year":"1990","unstructured":"Westermark P.; Engstr\u00f6m U.; Johnson K.H.; Westermark G.T.; Betsholtz C.; Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 1990,87(13),5036-5040","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s001250051175","volume":"42","author":"H\u00f6ppener J.W.","year":"1999","unstructured":"H\u00f6ppener J.W.; Oosterwijk C.; Nieuwenhuis M.G.; Posthuma G.; Thijssen J.H.; Vroom T.M.; Ahr\u00e9n B.; Lips C.J.; Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 1999,42(4),427-434","journal-title":"Diabetologia"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1074\/jbc.271.4.1988","volume":"271","author":"Mirzabekov T.A.","year":"1996","unstructured":"Mirzabekov T.A.; Lin M.C.; Kagan B.L.; Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem 1996,271(4),1988-1992","journal-title":"J Biol Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"11338","DOI":"10.1021\/bi020314u","volume":"41","author":"Anguiano M.","year":"2002","unstructured":"Anguiano M.; Nowak R.J.; Lansbury P.T.; Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002,41(38),11338-11343","journal-title":"Biochemistry"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"46363","DOI":"10.1074\/jbc.C400260200","volume":"279","author":"Kayed R.","year":"2004","unstructured":"Kayed R.; Sokolov Y.; Edmonds B.; McIntire T.M.; Milton S.C.; Hall J.E.; Glabe C.G.; Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004,279(45),46363-46366","journal-title":"J Biol Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"E1317","DOI":"10.1152\/ajpendo.00082.2006","volume":"291","author":"Meier J.J.","year":"2006","unstructured":"Meier J.J.; Kayed R.; Lin C.Y.; Gurlo T.; Haataja L.; Jayasinghe S.; Langen R.; Glabe C.G.; Butler P.C.; Inhibition of human IAPP fibril formation does not prevent \u03b2-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab 2006,291(6),E1317-E1324","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.2337\/db07-0197","volume":"56","author":"Huang C.J.","year":"2007","unstructured":"Huang C.J.; Lin C.Y.; Haataja L.; Gurlo T.; Butler A.E.; Rizza R.A.; Butler P.C.; High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated \u03b2-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 2007,56(8),2016-2027","journal-title":"Diabetes"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.pneurobio.2017.03.001","volume":"153","author":"Zhang Y.","year":"2017","unstructured":"Zhang Y.; Song W.; Islet amyloid polypeptide: another key molecule in Alzheimer\u2019s pathogenesis? Prog Neurobiol 2017,153,100-120","journal-title":"Prog Neurobiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.febslet.2013.01.046","volume":"587","author":"Cao P.","year":"2013","unstructured":"Cao P.; Marek P.; Noor H.; Patsalo V.; Tu L.H.; Wang H.; Abedini A.; Raleigh D.P.; Islet amyloid: from fundamental biophysics to mechanisms of cytotoxicity. FEBS Lett 2013,587(8),1106-1118","journal-title":"FEBS Lett"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.biochi.2010.12.012","volume":"93","author":"Ahmad E.","year":"2011","unstructured":"Ahmad E.; Ahmad A.; Singh S.; Arshad M.; Khan A.H.; Khan R.H.; A mechanistic approach for islet amyloid polypeptide aggregation to develop anti-amyloidogenic agents for type-2 diabetes. Biochimie 2011,93(5),793-805","journal-title":"Biochimie"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3390\/jcm9061713","volume":"9","author":"Stanciu G.D.","year":"2020","unstructured":"Stanciu G.D.; Bild V.; Ababei D.C.; Rusu R.N.; Cobzaru A.; Paduraru L.; Bulea D.; Link between diabetes and Alzheimer\u2019s disease due to the shared amyloid aggregation and deposition involving both neurodegenerative changes and neurovascular damages. J Clin Med 2020,9(6),1713","journal-title":"J Clin Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"474","DOI":"10.2337\/diabetes.53.2.474","volume":"53","author":"Janson J.","year":"2004","unstructured":"Janson J.; Laedtke T.; Parisi J.E.; O\u2019Brien P.; Petersen R.C.; Butler P.C.; Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004,53(2),474-481","journal-title":"Diabetes"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nature02621","volume":"430","author":"Mattson M.P.","year":"2004","unstructured":"Mattson M.P.; Pathways towards and away from Alzheimer\u2019s disease. Nature 2004,430(7000),631-639","journal-title":"Nature"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"29615","DOI":"10.1074\/jbc.R800019200","volume":"283","author":"Thinakaran G.","year":"2008","unstructured":"Thinakaran G.; Koo E.H.; Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008,283(44),29615-29619","journal-title":"J Biol Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nmeth.1432","volume":"7","author":"Maurer-Stroh S.","year":"2010","unstructured":"Maurer-Stroh S.; Debulpaep M.; Kuemmerer N.; Lopez de la Paz M.; Martins I.C.; Reumers J.; Morris K.L.; Copland A.; Serpell L.; Serrano L.; Schymkowitz J.W.; Rousseau F.; Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat Methods 2010,7(3),237-242","journal-title":"Nat Methods"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1515\/hsz-2018-0135","volume":"399","author":"Vitali V.","year":"2018","unstructured":"Vitali V.; Horn F.; Catania F.; Insulin-like signaling within and beyond metazoans. Biol Chem 2018,399(8),851-857","journal-title":"Biol Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.neuropharm.2017.09.016","volume":"136","author":"Bloom G.S.","year":"2018","unstructured":"Bloom G.S.; Lazo J.S.; Norambuena A.; Reduced brain insulin signaling: a seminal process in Alzheimer\u2019s disease pathogenesis. Neuropharmacology 2018,136(Pt B),192-195","journal-title":"Neuropharmacology"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrendo.2014.208","volume":"11","author":"Ziegler A.N.","year":"2015","unstructured":"Ziegler A.N.; Levison S.W.; Wood T.L.; Insulin and IGF receptor signalling in neural-stem-cell homeostasis. Nat Rev Endocrinol 2015,11(3),161-170","journal-title":"Nat Rev Endocrinol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.mad.2016.05.005","volume":"161","author":"Abolhassani N.","year":"2017","unstructured":"Abolhassani N.; Leon J.; Sheng Z.; Oka S.; Hamasaki H.; Iwaki T.; Nakabeppu Y.; Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative DNA damage in Alzheimer\u2019s disease brain. Mech Ageing Dev 2017,161(Pt A),95-104","journal-title":"Mech Ageing Dev"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"560375","DOI":"10.3389\/fendo.2020.560375","volume":"11","author":"Berlanga-Acosta J.","year":"2020","unstructured":"Berlanga-Acosta J.; Guill\u00e9n-Nieto G.; Rodr\u00edguez-Rodr\u00edguez N.; Bringas-Vega M.L.; Garc\u00eda-Del-Barco-Herrera D.; Berlanga-Saez J.O.; Garc\u00eda-Ojalvo A.; Vald\u00e9s-Sosa M.J.; Vald\u00e9s-Sosa P.A.; Insulin resistance at the crossroad of Alzheimer disease pathology: a review. Front Endocrinol (Lausanne) 2020,11,560375","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00424-020-02441-x","volume":"472","author":"Koepsell H.","year":"2020","unstructured":"Koepsell H.; Glucose transporters in brain in health and disease. Pflugers Arch 2020,472(9),1299-1343","journal-title":"Pflugers Arch"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1111\/j.1471-4159.2005.03155.x","volume":"93","author":"Mielke J.G.","year":"2005","unstructured":"Mielke J.G.; Taghibiglou C.; Liu L.; Zhang Y.; Jia Z.; Adeli K.; Wang Y.T.; A biochemical and functional characterization of diet-induced brain insulin resistance. J Neurochem 2005,93(6),1568-1578","journal-title":"J Neurochem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1084\/jem.20160493","volume":"213","author":"Stanley M.","year":"2016","unstructured":"Stanley M.; Macauley S.L.; Holtzman D.M.; Changes in insulin and insulin signaling in Alzheimer\u2019s disease: cause or consequence? J Exp Med 2016,213(8),1375-1385","journal-title":"J Exp Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1172\/JCI64595","volume":"123","author":"De Felice F.G.","year":"2013","unstructured":"De Felice F.G.; Alzheimer\u2019s disease and insulin resistance: translating basic science into clinical applications. J Clin Invest 2013,123(2),531-539","journal-title":"J Clin Invest"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1523\/JNEUROSCI.22-09-03376.2002","volume":"22","author":"Savage M.J.","year":"2002","unstructured":"Savage M.J.; Lin Y.G.; Ciallella J.R.; Flood D.G.; Scott R.W.; Activation of c-Jun N-terminal kinase and p38 in an Alzheimer\u2019s disease model is associated with amyloid deposition. J Neurosci 2002,22(9),3376-3385","journal-title":"J Neurosci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fphar.2015.00321","volume":"6","author":"Yarza R.","year":"2016","unstructured":"Yarza R.; Vela S.; Solas M.; Ramirez M.J.; c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer\u2019s disease. Front Pharmacol 2016,6,321","journal-title":"Front Pharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0014-5793(03)00438-1","volume":"546","author":"Johnston A.M.","year":"2003","unstructured":"Johnston A.M.; Pirola L.; Van Obberghen E.; Molecular mechanisms of insulin receptor substrate protein-mediated modulation of insulin signalling. FEBS Lett 2003,546(1),32-36","journal-title":"FEBS Lett"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fnmol.2012.00013","volume":"5","author":"Bradley C.A.","year":"2012","unstructured":"Bradley C.A.; Peineau S.; Taghibiglou C.; Nicolas C.S.; Whitcomb D.J.; Bortolotto Z.A.; Kaang B.K.; Cho K.; Wang Y.T.; Collingridge G.L.; A pivotal role of GSK-3 in synaptic plasticity. Front Mol Neurosci 2012,5,13","journal-title":"Front Mol Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1586\/ern.10.185","volume":"11","author":"Brietzke E.","year":"2011","unstructured":"Brietzke E.; Kapczinski F.; Grassi-Oliveira R.; Grande I.; Vieta E.; McIntyre R.S.; Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother 2011,11(7),1017-1028","journal-title":"Expert Rev Neurother"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1099\/vir.0.19771-0","volume":"85","author":"Cooray S.","year":"2004","unstructured":"Cooray S.; The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J Gen Virol 2004,85(Pt 5),1065-1076","journal-title":"J Gen Virol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/156720512799015037","volume":"9","author":"de la Monte S.M.","year":"2012","unstructured":"de la Monte S.M.; Brain insulin resistance and deficiency as therapeutic targets in Alzheimer\u2019s disease. Curr Alzheimer Res 2012,9(1),35-66","journal-title":"Curr Alzheimer Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0197-4580(03)00039-3","volume":"25","author":"Rensink A.A.","year":"2004","unstructured":"Rensink A.A.; Otte-H\u00f6ller I.; de Boer R.; Bosch R.R.; ten Donkelaar H.J.; de Waal R.M.; Verbeek M.M.; Kremer B.; Insulin inhibits amyloid \u03b2-induced cell death in cultured human brain pericytes. Neurobiol Aging 2004,25(1),93-103","journal-title":"Neurobiol Aging"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1073\/pnas.93.7.2719","volume":"93","author":"Hoshi M.","year":"1996","unstructured":"Hoshi M.; Takashima A.; Noguchi K.; Murayama M.; Sato M.; Kondo S.; Saitoh Y.; Ishiguro K.; Hoshino T.; Imahori K.; Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I\/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci USA 1996,93(7),2719-2723","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.neuroscience.2006.07.055","volume":"143","author":"Mielke J.G.","year":"2006","unstructured":"Mielke J.G.; Taghibiglou C.; Wang Y.T.; Endogenous insulin signaling protects cultured neurons from oxygen-glucose deprivation-induced cell death. Neuroscience 2006,143(1),165-173","journal-title":"Neuroscience"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pneurobio.2006.07.006","volume":"79","author":"Beurel E.","year":"2006","unstructured":"Beurel E.; Jope R.S.; The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006,79(4),173-189","journal-title":"Prog Neurobiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nature01640","volume":"423","author":"Phiel C.J.","year":"2003","unstructured":"Phiel C.J.; Wilson C.A.; Lee V.M.; Klein P.S.; GSK-3\u03b1 regulates production of Alzheimer\u2019s disease amyloid-\u03b2 peptides. Nature 2003,423(6938),435-439","journal-title":"Nature"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"7789","DOI":"10.1073\/pnas.90.16.7789","volume":"90","author":"Takashima A.","year":"1993","unstructured":"Takashima A.; Noguchi K.; Sato K.; Hoshino T.; Imahori K.; Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci USA 1993,90(16),7789-7793","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/mp.2013.4","volume":"18","author":"Llorens-Mart\u00edn M.","year":"2013","unstructured":"Llorens-Mart\u00edn M.; Fuster-Matanzo A.; Teixeira C.M.; Jurado-Arjona J.; Ulloa F.; Defelipe J.; R\u00e1bano A.; Hern\u00e1ndez F.; Soriano E.; \u00c1vila J.; GSK-3\u03b2 overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. Mol Psychiatry 2013,18(4),451-460","journal-title":"Mol Psychiatry"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"26369","DOI":"10.1074\/jbc.M110.121376","volume":"285","author":"Wei J.","year":"2010","unstructured":"Wei J.; Liu W.; Yan Z.; Regulation of AMPA receptor trafficking and function by glycogen synthase kinase 3. J Biol Chem 2010,285(34),26369-26376","journal-title":"J Biol Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s11064-006-9128-5","volume":"32","author":"Jope R.S.","year":"2007","unstructured":"Jope R.S.; Yuskaitis C.J.; Beurel E.; Glycogen Synthase Kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007,32(4-5),577-595","journal-title":"Neurochem Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/emboj\/20.1.27","volume":"20","author":"Lucas J.J.","year":"2001","unstructured":"Lucas J.J.; Hern\u00e1ndez F.; G\u00f3mez-Ramos P.; Mor\u00e1n M.A.; Hen R.; Avila J.; Decreased nuclear \u03b2-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3\u03b2 conditional transgenic mice. EMBO J 2001,20(1-2),27-39","journal-title":"EMBO J"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1172\/JCI64516","volume":"123","author":"Ly P.T.","year":"2013","unstructured":"Ly P.T.; Wu Y.; Zou H.; Wang R.; Zhou W.; Kinoshita A.; Zhang M.; Yang Y.; Cai F.; Woodgett J.; Song W.; Inhibition of GSK3\u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 2013,123(1),224-235","journal-title":"J Clin Invest"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"17214","DOI":"10.1074\/jbc.M112.445965","volume":"288","author":"Tao G.Z.","year":"2013","unstructured":"Tao G.Z.; Lehwald N.; Jang K.Y.; Baek J.; Xu B.; Omary M.B.; Sylvester K.G.; Wnt\/\u03b2-catenin signaling protects mouse liver against oxidative stress-induced apoptosis through the inhibition of forkhead transcription factor FoxO3. J Biol Chem 2013,288(24),17214-17224","journal-title":"J Biol Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4161\/org.4.2.5851","volume":"4","author":"Komiya Y.","year":"2008","unstructured":"Komiya Y.; Habas R.; Wnt signal transduction pathways. Organogenesis 2008,4(2),68-75","journal-title":"Organogenesis"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"12630","DOI":"10.1523\/JNEUROSCI.0277-12.2012","volume":"32","author":"Parker J.A.","year":"2012","unstructured":"Parker J.A.; Vazquez-Manrique R.P.; Tourette C.; Farina F.; Offner N.; Mukhopadhyay A.; Orfila A.M.; Darbois A.; Menet S.; Tissenbaum H.A.; Neri C.; Integration of \u03b2-catenin, sirtuin, and FOXO signaling protects from mutant huntingtin toxicity. J Neurosci 2012,32(36),12630-12640","journal-title":"J Neurosci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0896-6273(01)00433-0","volume":"31","author":"Lin C.H.","year":"2001","unstructured":"Lin C.H.; Yeh S.H.; Lin C.H.; Lu K.T.; Leu T.H.; Chang W.C.; Gean P.W.; A role for the PI-3 kinase signaling pathway in fear conditioning and synaptic plasticity in the amygdala. Neuron 2001,31(5),841-851","journal-title":"Neuron"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nn903","volume":"5","author":"Daw M.I.","year":"2002","unstructured":"Daw M.I.; Bortolotto Z.A.; Saulle E.; Zaman S.; Collingridge G.L.; Isaac J.T.; Phosphatidylinositol 3 kinase regulates synapse specificity of hippocampal long-term depression. Nat Neurosci 2002,5(9),835-836","journal-title":"Nat Neurosci"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1523\/JNEUROSCI.22-09-03359.2002","volume":"22","author":"Sanna P.P.","year":"2002","unstructured":"Sanna P.P.; Cammalleri M.; Berton F.; Simpson C.; Lutjens R.; Bloom F.E.; Francesconi W.; Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region. J Neurosci 2002,22(9),3359-3365","journal-title":"J Neurosci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"e3540","DOI":"10.1371\/journal.pone.0003540","volume":"3","author":"Kimura T.","year":"2008","unstructured":"Kimura T.; Yamashita S.; Nakao S.; Park J.M.; Murayama M.; Mizoroki T.; Yoshiike Y.; Sahara N.; Takashima A.; GSK-3\u03b2 is required for memory reconsolidation in adult brain. PLoS One 2008,3(10),e3540","journal-title":"PLoS One"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2741\/s310","volume":"4","author":"Oddo S.","year":"2012","unstructured":"Oddo S.; The role of mTOR signaling in Alzheimer disease. Front Biosci (Schol Ed) 2012,4,941-952","journal-title":"Front Biosci (Schol Ed)"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4161\/cbt.8.9.8210","volume":"8","author":"Zhang F.","year":"2009","unstructured":"Zhang F.; Beharry Z.M.; Harris T.E.; Lilly M.B.; Smith C.D.; Mahajan S.; Kraft A.S.; PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther 2009,8(9),846-853","journal-title":"Cancer Biol Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1074\/jbc.M110.180638","volume":"286","author":"Caccamo A.","year":"2011","unstructured":"Caccamo A.; Maldonado M.A.; Majumder S.; Medina D.X.; Holbein W.; Magr\u00ed A.; Oddo S.; Naturally secreted amyloid-\u03b2 increases mammalian Target of Rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem 2011,286(11),8924-8932","journal-title":"J Biol Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1242\/jcs.019265","volume":"120","author":"Nixon R.A.","year":"2007","unstructured":"Nixon R.A.; Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci 2007,120(Pt 23),4081-4091","journal-title":"J Cell Sci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1083\/jcb.201306041","volume":"203","author":"Betz C.","year":"2013","unstructured":"Betz C.; Hall M.N.; Where is mTOR and what is it doing there? J Cell Biol 2013,203(4),563-574","journal-title":"J Cell Biol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3858\/emm.2012.44.2.031","volume":"44","author":"Son J.H.","year":"2012","unstructured":"Son J.H.; Shim J.H.; Kim K.H.; Ha J.Y.; Han J.Y.; Neuronal autophagy and neurodegenerative diseases. Exp Mol Med 2012,44(2),89-98","journal-title":"Exp Mol Med"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11684-019-0729-1","volume":"14","author":"Zhang P.","year":"2020","unstructured":"Zhang P.; Li T.; Wu X.; Nice E.C.; Huang C.; Zhang Y.; Oxidative stress and diabetes: Antioxidative strategies. Front Med 2020,14(5),583-600","journal-title":"Front Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00424-010-0862-9","volume":"460","author":"Drews G.","year":"2010","unstructured":"Drews G.; Krippeit-Drews P.; D\u00fcfer M.; Oxidative stress and beta- cell dysfunction. Pflugers Arch 2010,460(4),703-718","journal-title":"Pflugers Arch"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"27905","DOI":"10.1074\/jbc.274.39.27905","volume":"274","author":"Maechler P.","year":"1999","unstructured":"Maechler P.; Jornot L.; Wollheim C.B.; Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic beta cells. J Biol Chem 1999,274(39),27905-27913","journal-title":"J Biol Chem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2337\/diabetes.50.4.803","volume":"50","author":"Lameloise N.","year":"2001","unstructured":"Lameloise N.; Muzzin P.; Prentki M.; Assimacopoulos-Jeannet F.; Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes 2001,50(4),803-809","journal-title":"Diabetes"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"30010","DOI":"10.1074\/jbc.M202066200","volume":"277","author":"Kaneto H.","year":"2002","unstructured":"Kaneto H.; Xu G.; Fujii N.; Kim S.; Bonner-Weir S.; Weir G.C.; Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 2002,277(33),30010-30018","journal-title":"J Biol Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"e12236","DOI":"10.14814\/phy2.12236","volume":"2","author":"Stuart C.A.","year":"2014","unstructured":"Stuart C.A.; Howell M.E.; Cartwright B.M.; McCurry M.P.; Lee M.L.; Ramsey M.W.; Stone M.H.; Insulin resistance and muscle insulin receptor substrate-1 serine hyperphosphorylation. Physiol Rep 2014,2(12),e12236","journal-title":"Physiol Rep"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3389\/fnins.2019.01444","volume":"13","author":"Llanos-Gonz\u00e1lez E.","year":"2020","unstructured":"Llanos-Gonz\u00e1lez E.; Henares-Chavarino \u00c1.A.; Pedrero-Prieto C.M.; Garc\u00eda-Carpintero S.; Fronti\u00f1\u00e1n-Rubio J.; Sancho-Bielsa F.J.; Alcain F.J.; Peinado J.R.; Rabanal-Ru\u00edz Y.; Dur\u00e1n-Prado M.; Interplay between mitochondrial oxidative disorders and proteostasis in Alzheimer\u2019s disease. Front Neurosci 2020,13,1444","journal-title":"Front Neurosci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"102294","DOI":"10.1016\/j.ctim.2019.102294","volume":"49","author":"Cassidy L.","year":"2020","unstructured":"Cassidy L.; Fernandez F.; Johnson J.B.; Naiker M.; Owoola A.G.; Broszczak D.A.; Oxidative stress in Alzheimer\u2019s disease: a review on emergent natural polyphenolic therapeutics. Complement Ther Med 2020,49,102294","journal-title":"Complement Ther Med"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","volume":"39","author":"Valko M.","year":"2007","unstructured":"Valko M.; Leibfritz D.; Moncol J.; Cronin M.T.; Mazur M.; Telser J.; Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007,39(1),44-84","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1042\/CS20150707","volume":"130","author":"Rak M.","year":"2016","unstructured":"Rak M.; B\u00e9nit P.; Chr\u00e9tien D.; Bouchereau J.; Schiff M.; El-Khoury R.; Tzagoloff A.; Rustin P.; Mitochondrial cytochrome c oxidase deficiency. Clin Sci (Lond) 2016,130(6),393-407","journal-title":"Clin Sci (Lond)"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.pharmthera.2019.02.011","volume":"198","author":"Elgenaidi I.S.","year":"2019","unstructured":"Elgenaidi I.S.; Spiers J.P.; Regulation of the phosphoprotein phosphatase 2A system and its modulation during oxidative stress: A potential therapeutic target? Pharmacol Ther 2019,198,68-89","journal-title":"Pharmacol Ther"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fncel.2020.00019","volume":"14","author":"Toral-Rios D.","year":"2020","unstructured":"Toral-Rios D.; Pichardo-Rojas P.S.; Alonso-Vanegas M.; Campos-Pe\u00f1a V.; GSK3\u03b2 and tau protein in Alzheimer\u2019s Disease and epilepsy. Front Cell Neurosci 2020,14,19","journal-title":"Front Cell Neurosci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2174\/1567205043332171","volume":"1","author":"Galbusera C.","year":"2004","unstructured":"Galbusera C.; Facheris M.; Magni F.; Galimberti G.; Sala G.; Tremolada L.; Isella V.; Guerini F.R.; Appollonio I.; Galli-Kienle M.; Ferrarese C.; Increased susceptibility to plasma lipid peroxidation in Alzheimer disease patients. Curr Alzheimer Res 2004,1(2),103-109","journal-title":"Curr Alzheimer Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1212\/WNL.45.8.1594","volume":"45","author":"Lovell M.A.","year":"1995","unstructured":"Lovell M.A.; Ehmann W.D.; Butler S.M.; Markesbery W.R.; Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer\u2019s disease. Neurology 1995,45(8),1594-1601","journal-title":"Neurology"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00401-002-0523-y","volume":"104","author":"Dei R.","year":"2002","unstructured":"Dei R.; Takeda A.; Niwa H.; Li M.; Nakagomi Y.; Watanabe M.; Inagaki T.; Washimi Y.; Yasuda Y.; Horie K.; Miyata T.; Sobue G.; Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer\u2019s disease. Acta Neuropathol 2002,104(2),113-122","journal-title":"Acta Neuropathol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.bbadis.2011.08.012","volume":"1812","author":"Swerdlow R.H.","year":"2011","unstructured":"Swerdlow R.H.; Brain aging, Alzheimer\u2019s disease, and mitochondria. Biochim Biophys Acta Mol Basis Dis 2011,1812(12),1630-1639","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s10072-019-03863-x","volume":"40","author":"Tobore T.O.","year":"2019","unstructured":"Tobore T.O.; On the central role of mitochondria dysfunction and oxidative stress in Alzheimer\u2019s disease. Neurol Sci 2019,40(8),1527-1540","journal-title":"Neurol Sci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrneurol.2010.130","volume":"6","author":"Sims-Robinson C.","year":"2010","unstructured":"Sims-Robinson C.; Kim B.; Rosko A.; Feldman E.L.; How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 2010,6(10),551-559","journal-title":"Nat Rev Neurol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1007\/s12035-017-0825-7","volume":"55","author":"Infante-Garcia C.","year":"2018","unstructured":"Infante-Garcia C.; Ramos-Rodriguez J.J.; Hierro-Bujalance C.; Ortegon E.; Pickett E.; Jackson R.; Hernandez-Pacho F.; Spires-Jones T.; Garcia-Alloza M.; Antidiabetic polypill improves central pathology and cognitive impairment in a mixed model of Alzheimer\u2019s disease and type 2 diabetes. Mol Neurobiol 2018,55(7),6130-6144","journal-title":"Mol Neurobiol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbi.2017.12.009","volume":"69","author":"Ou Z.","year":"2018","unstructured":"Ou Z.; Kong X.; Sun X.; He X.; Zhang L.; Gong Z.; Huang J.; Xu B.; Long D.; Li J.; Li Q.; Xu L.; Xuan A.; Metformin treatment prevents amyloid plaque deposition and memory impairment in APP\/PS1 mice. Brain Behav Immun 2018,69,351-363","journal-title":"Brain Behav Immun"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/jnc.13248","volume":"135","author":"Ma D.L.","year":"2015","unstructured":"Ma D.L.; Chen F.Q.; Xu W.J.; Yue W.Z.; Yuan G.; Yang Y.; Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db\/db mice. J Neurochem 2015,135(2),301-308","journal-title":"J Neurochem"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.5056","volume":"245","author":"Batista A.F.","year":"2018","unstructured":"Batista A.F.; Forny-Germano L.; Clarke J.R.; Lyra E Silva N.M.; Brito-Moreira J.; Boehnke S.E.; Winterborn A.; Coe B.C.; Lablans A.; Vital J.F.; Marques S.A.; Martinez A.M.; Gralle M.; Holscher C.; Klein W.L.; Houzel J.C.; Ferreira S.T.; Munoz D.P.; De Felice F.G.; The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease. J Pathol 2018,245(1),85-100","journal-title":"J Pathol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2012.03.016","volume":"11","author":"Wang J.","year":"2012","unstructured":"Wang J.; Gallagher D.; DeVito L.M.; Cancino G.I.; Tsui D.; He L.; Keller G.M.; Frankland P.W.; Kaplan D.R.; Miller F.D.; Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 2012,11(1),23-35","journal-title":"Cell Stem Cell"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JAD-150493","volume":"51","author":"Luchsinger J.A.","year":"2016","unstructured":"Luchsinger J.A.; Perez T.; Chang H.; Mehta P.; Steffener J.; Pradabhan G.; Ichise M.; Manly J.; Devanand D.P.; Bagiella E.; Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. J Alzheimers Dis 2016,51(2),501-514","journal-title":"J Alzheimers Dis"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1176\/appi.ajgp.13.11.950","volume":"13","author":"Watson G.S.","year":"2005","unstructured":"Watson G.S.; Cholerton B.A.; Reger M.A.; Baker L.D.; Plymate S.R.; Asthana S.; Fishel M.A.; Kulstad J.J.; Green P.S.; Cook D.G.; Kahn S.E.; Keeling M.L.; Craft S.; Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005,13(11),950-958","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","volume":"32","author":"Sato T.","year":"2011","unstructured":"Sato T.; Hanyu H.; Hirao K.; Kanetaka H.; Sakurai H.; Iwamoto T.; Efficacy of PPAR-\u03b3 agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011,32(9),1626-1633","journal-title":"Neurobiol Aging"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.dsx.2018.03.002","volume":"12","author":"Yildirim Simsir I.","year":"2018","unstructured":"Yildirim Simsir I.; Soyaltin U.E.; Cetinkalp S.; Glucagon Like Peptide-1 (GLP-1) likes Alzheimer\u2019s disease. Diabetes Metab Syndr 2018,12(3),469-475","journal-title":"Diabetes Metab Syndr"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.exger.2009.12.004","volume":"45","author":"D\u2019Amico M.","year":"2010","unstructured":"D\u2019Amico M.; Di Filippo C.; Marfella R.; Abbatecola A.M.; Ferraraccio F.; Rossi F.; Paolisso G.; Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer\u2019s prone mice. Exp Gerontol 2010,45(3),202-207","journal-title":"Exp Gerontol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s12264-018-00336-7","volume":"35","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Xie J.Z.; Xu X.Y.; Hu J.; Xu T.; Jin S.; Yang S.J.; Wang J.Z.; Liraglutide ameliorates hyperhomocysteinemia-induced Alzheimer-like pathology and memory deficits in rats via multi-molecular targeting. Neurosci Bull 2019,35(4),724-734","journal-title":"Neurosci Bull"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"e01505","DOI":"10.1002\/brb3.1505","volume":"10","author":"Li C.","year":"2020","unstructured":"Li C.; Liu W.; Li X.; Zhang Z.; Qi H.; Liu S.; Yan N.; Xing Y.; H\u00f6lscher C.; Wang Z.; The novel GLP-1\/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the ICV. STZ rat model of AD. Brain Behav 2020,10(3),e01505","journal-title":"Brain Behav"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12031-019-1257-9","volume":"67","author":"Robinson A.","year":"2019","unstructured":"Robinson A.; Lubitz I.; Atrakchi-Baranes D.; Licht-Murava A.; Katsel P.; Leroith D.; Liraz-Zaltsman S.; Haroutunian V.; Beeri M.S.; Combination of insulin with a GLP1 agonist is associated with better memory and normal expression of insulin receptor pathway genes in a mouse model of Alzheimer\u2019s disease. J Mol Neurosci 2019,67(4),504-510","journal-title":"J Mol Neurosci"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.2147\/IJN.S171490","volume":"13","author":"Silva-Abreu M.","year":"2018","unstructured":"Silva-Abreu M.; Calpena A.C.; Andr\u00e9s-Benito P.; Aso E.; Romero I.A.; Roig-Carles D.; Gromnicova R.; Espina M.; Ferrer I.; Garc\u00eda M.L.; Male D.; PPAR\u03b3 agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer\u2019s disease: in vitro and in vivo studies. Int J Nanomedicine 2018,13,5577-5590","journal-title":"Int J Nanomedicine"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/npp.2010.32","volume":"35","author":"Escribano L.","year":"2010","unstructured":"Escribano L.; Sim\u00f3n A.M.; Gimeno E.; Cuadrado-Tejedor M.; L\u00f3pez de Maturana R.; Garc\u00eda-Osta A.; Ricobaraza A.; P\u00e9rez-Mediavilla A.; Del R\u00edo J.; Frechilla D.; Rosiglitazone rescues memory impairment in Alzheimer\u2019s transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010,35(7),1593-1604","journal-title":"Neuropsychopharmacology"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cmet.2013.11.002","volume":"18","author":"Lourenco M.V.","year":"2013","unstructured":"Lourenco M.V.; Clarke J.R.; Frozza R.L.; Bomfim T.R.; Forny-Germano L.; Batista A.F.; Sathler L.B.; Brito-Moreira J.; Amaral O.B.; Silva C.A.; Freitas-Correa L.; Esp\u00edrito-Santo S.; Campello-Costa P.; Houzel J.C.; Klein W.L.; Holscher C.; Carvalheira J.B.; Silva A.M.; Velloso L.A.; Munoz D.P.; Ferreira S.T.; De Felice F.G.; TNF-\u03b1 mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer\u2019s \u03b2-amyloid oligomers in mice and monkeys. Cell Metab 2013,18(6),831-843","journal-title":"Cell Metab"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.bbrc.2017.11.114","volume":"495","author":"Cai H.Y.","year":"2018","unstructured":"Cai H.Y.; Yang J.T.; Wang Z.J.; Zhang J.; Yang W.; Wu M.N.; Qi J.S.; Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP\/PS1\/tau mouse model of Alzheimer\u2019s disease. Biochem Biophys Res Commun 2018,495(1),1034-1040","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.trci.2019.05.004","volume":"5","author":"Knodt A.R.","year":"2019","unstructured":"Knodt A.R.; Burke J.R.; Welsh-Bohmer K.A.; Plassman B.L.; Burns D.K.; Brannan S.K.; Kukulka M.; Wu J.; Hariri A.R.; Effects of pioglitazone on mnemonic hippocampal function: a blood oxygen level-dependent functional magnetic resonance imaging study in elderly adults. Alzheimers Dement (N Y) 2019,5,254-263","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3233\/JAD-161256","volume":"57","author":"Craft S.","year":"2017","unstructured":"Craft S.; Claxton A.; Baker L.D.; Hanson A.J.; Cholerton B.; Trittschuh E.H.; Dahl D.; Caulder E.; Neth B.; Montine T.J.; Jung Y.; Maldjian J.; Whitlow C.; Friedman S.; Effects of regular and long-acting insulin on cognition and Alzheimer\u2019s disease biomarkers: a pilot clinical trial. J Alzheimers Dis 2017,57(4),1325-1334","journal-title":"J Alzheimers Dis"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","volume":"123","author":"Isik A.T.","year":"2017","unstructured":"Isik A.T.; Soysal P.; Yay A.; Usarel C.; The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer\u2019s disease. Diabetes Res Clin Pract 2017,123,192-198","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","volume":"70","author":"Reger M.A.","year":"2008","unstructured":"Reger M.A.; Watson G.S.; Green P.S.; Wilkinson C.W.; Baker L.D.; Cholerton B.; Fishel M.A.; Plymate S.R.; Breitner J.C.; DeGroodt W.; Mehta P.; Craft S.; Intranasal insulin improves cognition and modulates \u03b2-amyloid in early AD. Neurology 2008,70(6),440-448","journal-title":"Neurology"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1210\/jc.2007-2606","volume":"93","author":"Benedict C.","year":"2008","unstructured":"Benedict C.; Kern W.; Schultes B.; Born J.; Hallschmid M.; Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 2008,93(4),1339-1344","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1474-4422(11)70188-0","volume":"10","author":"Launer L.J.","year":"2011","unstructured":"Launer L.J.; Miller M.E.; Williamson J.D.; Lazar R.M.; Gerstein H.C.; Murray A.M.; Sullivan M.; Horowitz K.R.; Ding J.; Marcovina S.; Lovato L.C.; Lovato J.; Margolis K.L.; O\u2019Connor P.; Lipkin E.W.; Hirsch J.; Coker L.; Maldjian J.; Sunshine J.L.; Truwit C.; Davatzikos C.; Bryan R.N.; Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011,10(11),969-977","journal-title":"Lancet Neurol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1001\/jamainternmed.2013.6176","volume":"173","author":"Yaffe K.","year":"2013","unstructured":"Yaffe K.; Falvey C.M.; Hamilton N.; Harris T.B.; Simonsick E.M.; Strotmeyer E.S.; Shorr R.I.; Metti A.; Schwartz A.V.; Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med 2013,173(14),1300-1306","journal-title":"JAMA Intern Med"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527320666211110115257","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197876\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527320666211110115257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T04:19:46Z","timestamp":1656821986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197876\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":141,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527320666211110115257","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}